eQTLGen Phase 1

Source: https://www.eqtlgen.org/phase1.html


Publication: Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression

PubMed ID: 34475573

Citation: Võsa U, Claringbould A, Westra HJ, et al. Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. Nat Genet. 2021;53(9):1300-1310. doi:10.1038/s41588-021-00913-z

Funding: This work is supported by a grant from the European Research Council (ERC, ERC Starting Grant agreement number 637640 ImmRisk), a VIDI grant (917.14.374) and VICI grant from the Netherlands Organisation for Scientific Research (NWO) to L.F. This work has been supported by the European Regional Development Fund and the programme Mobilitas Pluss (MOBTP108) to U.V. The project was supported by Foundation “De Drie Lichten” in the Netherlands with a grant to A.C. M.G.N. is supported by ZonMw grants 849200011 and 531003014 from The Netherlands Organisation for Health Research and Development, a VENI grant from NWO (VI.Veni.191G.030) and a Jacobs foundation research fellowship. H.Y. is funded by a Diabetes UK RD Lawrence fellowship (17/0005594). This project received funding from the ERC under the European Union’s Horizon 2020 research and innovation programme (grant agreement n° 772376 - EScORIAL) to J.H.V. T.E. and A.K. were supported by the Estonian Research Council grant PRG (PRG1291). A.Ba. was supported by NIH grant 1R01MH109905, NIH grant R01HG008150 (NHGRI; Non-Coding Variants Program) and NIH grant R01MH101814 (NIH Common Fund; GTEx Program). M.v.d.W was funded by Nederlandse Organisatie voor Wetenschappelijk onderzoek, NWO-Veni 192.029. This work was supported by National Institutes of Health grants R21ES024834 (B.P. and M.A.), R01ES020506 (B.P.), R01ES023834 (B.P.), R35ES028379 (B.P.), R01 GM108711 (L.C.), and R01CA107431 (H.A.). This work was supported through The Sigrid Juselius Foundation (J.Ke.) and funds from the Academy of Finland [grant numbers 297338 and 307247] (J.Ke.) and Novo Nordisk Foundation [grant number NNF17OC0026062] (J.Ke.). S.Ri. was supported by the Academy of Finland Centre of Excellence in Complex Disease Genetics (Grant No. 312062). M.G. was supported by EU Horizon 2020 (grant 733100 for SYSCID); and grant from EOS excellence of Science (FNRS and FWO) (gnaf N° 30770923). We acknowledge support from BBMRI–NL (Biobanking and Biomolecular Resources Research Infrastructure 184.021.007 and 184.033.111); Spinozapremie (NWO- 56–464-14192), the European Research Council (ERC Advanced 230374) and KNAW Academy Professor Award (PAH/6635) to D.I.B. G.H. works in a unit that receives funding from the UK MRC (MC_UU_12013/1&2&5) and the University of Bristol. S.B. was supported by the Swiss National Science Foundation (310030–152724). This work was supported by the German Federal Ministry of Education and Research (BMBF) within the framework of the e:Med research and funding concept (grant # 01ZX1906B), and by LIFE – Leipzig Research Center for Civilization Diseases, Universität Leipzig (which is funded by means of the European Union, by the European Regional Development Fund (ERDF) and by means of the Free State of Saxony within the framework of the excellence initiative to H.K. and M.Sc.